SAN DIEGO, Sept. 6 2017 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), a leading medical device company focused on
transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced that it has
received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) for use of the Company's redesigned MAGEC®
system with its RELINE® Small Stature system. NuVasive will feature
these new product offerings at the Scoliosis Research Society (SRS)
52nd Annual Meeting & Course to be held September 6-9, 2017 in Philadelphia.
The MAGEC system uses innovative magnetic technology within
adjustable growing rods to treat early-onset scoliosis in a less
invasive manner. The latest advancements to the MAGEC system
include redesigned components to help provide ease-of-use for the
surgeon and help make surgical outcomes more reproducible. In
addition, the MAGEC system is introducing a new 5.0 millimeter rod
diameter offering, that when paired with the low-profile RELINE
Small Stature system, is designed to provide optimal strength to
growing-rod constructs to help improve clinical outcomes.
RELINE Small Stature is a comprehensive pediatric deformity
fixation system allowing to achieve optimal construct strength with
a reduced implant profile. RELINE Small Stature is the only small
stature system that is compatible with the new 5.0 millimeter MAGEC
rod.
"As a low-profile pediatric fixation system, RELINE Small
Stature is the first-of-its-kind system to offer
competitively-sized pediatric implants that accept up to a 5.0mm
rod," said Matt Link, executive vice
president of strategy, technology and corporate development at
NuVasive. "The clearance for our redesigned MAGEC system with
RELINE Small Stature highlights our speed to market and our further
commitment to bringing procedural solutions that transform care to
the pediatric deformity market."
NuVasive has reached meaningful gains in both the adult and
pediatric deformity markets, a $2.5
billion opportunity over the last two years and is a leading
sponsor of SRS. The Company's 'Embracing the Journey Together'
initiative includes pediatric spinal deformity research, education
and spinal deformity event support, assisting leading surgeons as
they educate other surgeons around the world.
NuVasive will showcase its market-leading,
procedurally-integrated technologies in Meeting Room #406 at
the Philadelphia Marriot Downtown. Visit here for more details.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is transforming spine surgery and
beyond with minimally invasive, procedurally-integrated solutions
designed to deliver reproducible and clinically-proven surgical
outcomes. The Company's portfolio includes access instruments,
implantable hardware, biologics, software systems for surgical
planning, navigation and imaging solutions, magnetically adjustable
implant systems for spine and orthopedics, and intraoperative
monitoring service offerings. With $962
million in revenues (2016), NuVasive has an approximate
2,300 person workforce in more than 40 countries serving surgeons,
hospitals and patients. For more information, please visit
www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this news
release that are not a description of historical facts are
forward-looking statements that involve risks, uncertainties,
assumptions and other factors which, if they do not materialize or
prove correct, could cause NuVasive's results to differ materially
from historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties
which contribute to the uncertain nature of these statements
include, among others, risks associated with acceptance of the
Company's surgical products and procedures by spine surgeons,
development and acceptance of new products or product enhancements,
clinical and statistical verification of the benefits achieved via
the use of NuVasive's products (including the iGA™ platform), the
Company's ability to effectually manage inventory as it continues
to release new products, its ability to recruit and retain
management and key personnel, and the other risks and uncertainties
described in NuVasive's news releases and periodic filings with the
Securities and Exchange Commission. NuVasive's public filings with
the Securities and Exchange Commission are available at
www.sec.gov. NuVasive assumes no obligation to update any
forward-looking statement to reflect events or circumstances
arising after the date on which it was made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-receives-fda-510k-clearance-for-leading-eos-innovation-300514377.html
SOURCE NuVasive, Inc.